23andMe

Offers direct-to-consumer personal genome testing via swabbed saliva samples collected and sent by consumer. 23andMe, a consumer genetics company, is going public via a merger with Richard Branson's special purpose acquisition corporation (SPAC) VG Acquisition Corp. VGAC, 10.88%, in a deal with an enterprise value of about $3.5 billion, the companies said Thursday February 4 2021. 23andMe co-Founder Anne Wojcicki and Richard Branson are investing $25 million in the company, which will have a pro forma cash balance of more than $900 million at closing. The deal is expected to close in the second quarter. VG Acquisition shares jumped 12% premarket on the news.